Collegium Pharmaceutical Inc (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical Inc · NASDAQ
$23.40-0.13 (-0.55%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Collegium Pharmaceutical Inc, 4 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $43.00 to $60.00, so the covering firms are broadly aligned. The average target of $49.00 sits 109% above the current $23.40. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.99 next quarter toward $6.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Collegium Pharmaceutical Inc.
As of Sep, 4 of 5 firms rate COLL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
COLL EPS & revenue forecast
EPS · NEXT QUARTER
$1.99
Range $1.90 – $2.09 · 4 analysts · -2% YoY
Next period, 4 analysts expect Collegium Pharmaceutical Inc to earn $1.99 a share (range $1.90 – $2.09), versus $2.04 a year earlier. Full-year consensus is $7.47, growing to $6.77 the year after.
REVENUE · NEXT QUARTER
$224.9M
Range $221.2M – $230.0M · 4 analysts · +9% YoY
Revenue is expected to reach $224.9M (range $221.2M – $230.0M), +9.5% year-over-year. Full-year consensus is $836.8M, rising to $828.1M next year.
Top analysts covering Collegium Pharmaceutical Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on COLL.
#1
Serge Belanger
Needham · Rank #105
Buy
$46.00+96.6% to target
Overall win rate
48%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #107
Hold
$43.00+83.8% to target
Overall win rate
50%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #170
Buy
$50.00+113.7% to target
Overall win rate
54%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$60.00+156.4% to target
Overall win rate
42%
+ Follow
#5
GS
Glen Santangelo
Barclays
Buy
$48.00+105.1% to target
Coverage
—
+ Follow
COLL stock forecast FAQ
What is COLL's average 12-month price target?+
The 5 analysts with a live target average $49.00 for Collegium Pharmaceutical Inc over the next 12 months, ranging from a $60.00 high to a $43.00 low.
Is COLL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for COLL?+
The Street-high target is $60.00 (HC Wainwright & Co.), and the Street-low is $43.00 (Piper Sandler). The average of all 5 active targets is $49.00.
How many Wall Street analysts cover COLL?+
5 analysts have an active rating on Collegium Pharmaceutical Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering COLL?+
Among analysts who currently cover COLL, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #105). Their current call is Buy with a $46.00 target.
What is Collegium Pharmaceutical Inc's projected EPS for next quarter?+
The consensus estimate is $1.99 per share (range $1.90 – $2.09) across 4 analysts. Full-year EPS is projected at $7.47, rising to $6.77 the following year.
How much revenue is Collegium Pharmaceutical Inc expected to report next quarter?+
Consensus revenue is $224.9M (range $221.2M – $230.0M). Full-year revenue is projected at $836.8M, growing to $828.1M next year.
Have analysts been upgrading or downgrading COLL lately?+
As of Sep, 4 of 5 firms rate COLL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their COLL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
